^
Association details:
| Biomarker: | HER-2 overexpression |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) + MM-302 (Topoisomerase II inhibitor, HER2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Dual HER2 Targeting with Trastuzumab and Liposomal-Encapsulated Doxorubicin (MM-302) Demonstrates Synergistic Antitumor Activity in Breast and Gastric Cancer
Excerpt:
In this study, we evaluated the feasibility and preclinical activity of combining MM-302 with trastuzumab….Finally, the combination of MM-302 and trastuzumab induced synergistic antitumor activity in HER2-overexpressing xenograft models of breast and gastric cancer.
DOI:
https://doi.org/10.1158/0008-5472.CAN-15-1518
